Banque Pictet & Cie SA Has $25.83 Million Stake in Boston Scientific Corporation $BSX

Banque Pictet & Cie SA lowered its position in Boston Scientific Corporation (NYSE:BSX) by 13.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 270,871 shares of the medical equipment provider’s stock after selling 41,572 shares during the period. Banque Pictet & Cie SA’s holdings in Boston Scientific were worth $25,828,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Gerber Kawasaki Wealth & Investment Management grew its holdings in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC raised its stake in shares of Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares during the last quarter. Claret Asset Management Corp raised its stake in shares of Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its position in Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 103 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its position in Boston Scientific by 2.3% in the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider’s stock valued at $466,000 after buying an additional 108 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CHAMPION‑AF trial met all primary and key secondary endpoints for the WATCHMAN FLX versus NOACs — clinical data supports the WATCHMAN franchise and stroke-prevention positioning, which is bullish for long-term device revenues. Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
• Positive Sentiment: Boston Scientific completed its acquisition of Valencia Technologies — expands product pipeline/technology footprint (supports tuck‑in growth and cross‑sell opportunities). Boston Scientific completes Valencia Technologies acquisition
• Positive Sentiment: Additional clinical/data wins and study support for intravascular ultrasound (IVUS) in PCI underscore minimally invasive care leadership — a structural growth thesis for cardiovascular devices. Boston Scientific study backs use of intravascular ultrasound in PCI
• Neutral Sentiment: Some analysts reiterated positive views (RBC, Needham, Raymond James earlier reaffirmations), and long‑term bull pieces highlight durable growth — supports case for recovery if execution stabilizes. Boston Scientific (NYSE:BSX) Earns “Outperform” Rating from Royal Bank Of Canada
• Negative Sentiment: Raymond James downgraded the stock and cut estimates amid concerns about U.S. electrophysiology trends and Watchman uptake, which triggered a sharp share decline and hurt near‑term sentiment. Raymond James downgrades Boston Scientific but long-term story remains intact
• Negative Sentiment: Unusually large put‑option volume today (put buying jumped ~205%) signals elevated short‑term hedging or bearish bets from traders, adding downside pressure. Options activity report
• Negative Sentiment: Multiple law firms have filed or solicited investors for securities‑fraud class actions tied to allegations about disclosure of electrophysiology volumes and related issues — legal risk and potential litigation costs are headline negatives for sentiment. Bronstein class action notice

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Robert W. Baird lowered their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Truist Financial cut their target price on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. JPMorgan Chase & Co. lowered their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Wells Fargo & Company dropped their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $104.36.

Boston Scientific Stock Down 1.2%

Shares of NYSE:BSX opened at $62.01 on Thursday. The company has a 50 day moving average price of $75.78 and a two-hundred day moving average price of $89.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a market capitalization of $92.15 billion, a PE ratio of 31.96, a PEG ratio of 0.97 and a beta of 0.78. Boston Scientific Corporation has a 52 week low of $61.24 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the firm earned $0.70 earnings per share. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.